Souhaitez-vous accéder aux communiqués récents ?

Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants...

The chemical synthesis peptide drugs market is valued at US$ 2.74 bn in 2025 and is projected to reach US$ 4.82 bn by 2034, growing at a CAGR of 6.54%.

Delray Beach, FL, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Rapid innovation, expanding clinical pipelines, and rising demand for curative treatments position gene therapy as a transformative growth engine...

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to...

The cell & gene therapy market is a rapidly growing sector that involves the use of cellular and genetic materials to treat various diseases and condition.

TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in...

According to market research the hemophilia inhibitors market growth is driven by emerging trends and strong demand across key sectors

Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer’s disease by up to 8.3 years in low-amyloid group who started...

TOKYO and CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...